Cargando…

Letter Regarding “Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations”

Detalles Bibliográficos
Autores principales:	Rico-Fontalvo, Jorge, Cabrales, Jose, Rodriguez-Yanez, Tomás, Daza-Arnedo, Rodrigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751679/ https://www.ncbi.nlm.nih.gov/pubmed/36531869 http://dx.doi.org/10.1016/j.ekir.2022.08.017

Ejemplares similares

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Letter Regarding “Moderating Effects in Randomized Trials—Interpreting the P Value, Confidence Intervals, and Hazard Ratios”
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022)

Molecular Mechanisms of Diabetic Kidney Disease
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022)

Novel Biomarkers of Diabetic Kidney Disease
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2023)

Critically Ill Patients with Renal Hyperfiltration: Optimizing Antibiotic Dose
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2023)

Obesity Weight Loss Phenotypes in CKD: Measured GFR and Albumin-to-Creatinine Excretion Ratio Place for Stratification
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2023)

Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
por: Daza-Arnedo, Rodrigo, et al.
Publicado: (2021)

Insulin and the kidneys: a contemporary view on the molecular basis
por: Daza-Arnedo, Rodrigo, et al.
Publicado: (2023)

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD
por: Noel, J. Ariana, et al.
Publicado: (2022)

Response to Letter from Dr. Volbeda and Colleagues Regarding COVID-19 and CKD
por: Sörling, Annika, et al.
Publicado: (2023)

Letter Regarding “Association Between CKD, Obesity, Cardiometabolic Risk Factors, and Severe COVID-19 Outcomes”
por: Volbeda, Meint, et al.
Publicado: (2023)

SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
por: Thomas, Merlin C, et al.
Publicado: (2023)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

Obesity Indices and the Risk of CKD
por: Tsuboi, Nobuo
Publicado: (2021)

Letter Regarding “Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR”
por: Zhao, Li-Min, et al.
Publicado: (2021)

Unmet Needs of CKD in Latin America: A Review from Expert Virtual Working Group
por: Correa-Rotter, Ricardo, et al.
Publicado: (2023)

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
por: Fernandez-Fernandez, Beatriz, et al.
Publicado: (2020)

Nephroprotection by SGLT2i in CKD Patients: May It Be Modulated by Low-Protein Plant-Based Diets?
por: Cupisti, Adamasco, et al.
Publicado: (2020)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

A pilot qualitative study to explore stakeholder opinions regarding prescribing quality indicators
por: Martirosyan, Liana, et al.
Publicado: (2012)

Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
por: Bernardi, Marco, et al.
Publicado: (2023)

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
por: Androutsakos, Theodoros, et al.
Publicado: (2022)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: A meta-analysis
por: Li, Ning, et al.
Publicado: (2022)

SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis
por: Mavrakanas, Thomas A., et al.
Publicado: (2023)

Toric intraocular lenses: Expanding indications and preoperative and surgical considerations to improve outcomes
por: Singh, Vivek Mahendrapratap, et al.
Publicado: (2022)

Letter to the Editor Regarding “Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation”
por: Chhabra, Saurabh, et al.
Publicado: (2020)

Prevalence of Chronic Infection by Hepatitis C Virus in Asymptomatic Population With Risk Factors in Cartagena, Colombia
por: Imbeth-Acosta, Pedro, et al.
Publicado: (2022)

Diagnostic Indicators of Superimposed Preeclampsia in Women With CKD
por: Wiles, Kate, et al.
Publicado: (2019)

Disparities in the Use of SGLT2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Adults With CKD in the United States
por: Nicholas, Susanne B., et al.
Publicado: (2022)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Comment on: Toric intraocular lenses: Expanding indications and preoperative and surgical considerations to improve outcomes
por: Dudani, Ajay I, et al.
Publicado: (2022)

Letter to the Editor Regarding “Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community”
por: Mishra, Ajay Kumar, et al.
Publicado: (2020)

Letter to Editor Regarding the OCEAN Study [Letter]
por: Yawn, Barbara P, et al.
Publicado: (2021)

SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use
por: Hosokawa, Yusei, et al.
Publicado: (2020)

When to Use Antibiotics in COVID-19: A Proposal Based on Questions
por: Dueñas-Castell, Carmelo, et al.
Publicado: (2022)

Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

In Reply to the Letter to the Editor Regarding “Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community”
por: Scullen, Tyler, et al.
Publicado: (2020)

Hiperkalemia crónica, diagnóstico y manejo. Consenso colombiano
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f5q0dqgg7hd7bsa69k3863ipl1